Clinical Trials
73 trialsOCTANE
University Health Network, Toronto
TRACK
TargetCancer Foundation
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
SHERLOCK
University Health Network, Toronto
iCaRe2
University of Nebraska
CUPem
Imperial College London
PaCIFiC-CUP Classifies Cancer of Unknown Primary
Sun Yat-sen University
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
M.D. Anderson Cancer Center
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
University of Texas Southwestern Medical Center
Cancer Genetic Testing in Ethnic Populations
Mayo Clinic
EGGCUP
The Christie NHS Foundation Trust
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
18F-FAPI PET in Cancers of Unknown Primary Site
First Affiliated Hospital of Zhejiang University
NorCUP
Haukeland University Hospital
IMPACT
University Health Network, Toronto
CAPTIV-8
British Columbia Cancer Agency
CUP
AHS Cancer Control Alberta
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
ACROPOLI
SOLTI Breast Cancer Research Group
GENIUS
University Health Network, Toronto
VISIONARY
Peking University
CUP-COMP
The Christie NHS Foundation Trust
OP-CUP
Rigshospitalet, Denmark
HARE-40
University of Southampton
AGNOSTOS
Fondazione del Piemonte per l'Oncologia
REFLECT
University Medical Center Groningen
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
Mayo Clinic
TOFFEE
University of Edinburgh
FAPI-CUP
Peter MacCallum Cancer Centre, Australia
Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS
Rigshospitalet, Denmark
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary
Fudan University
Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
Fudan University
Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin
Burzynski Research Institute
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
University of Chicago
CheCUP
University Hospital Heidelberg
GEFCAPI04
Gustave Roussy, Cancer Campus, Grand Paris
E-MOSAIC Electronic Tool to Monitor Symptoms
Swiss Cancer Institute
Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
EPAC
Stanford University
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Montefiore Medical Center
PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
Wake Forest University Health Sciences
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
St. Jude Children's Research Hospital
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
High-dose ICE With Amifostine
Dana-Farber Cancer Institute